References
- Makanokaweyoon S, Limson-Pobre R NR, Moreia A L, Schauf V, Kaplan G. Thalidomi.de inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90: 5974–8
- Moreira A, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Ex. Med 1993; 177: 1675–80
- Sampaio E P, Sarno E N, Galilly R, Cohn Z A, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Ex. Med 1991; 173: 699–703
- Nishimura K, Hashimoto Y, Iwasaki S. Enhancement of phorbol ester-induced production of tumor necrosis factor α by thalidomide. 1994; 199(2)455–60
- Faigle J W, Kerberle H R, Schmid K. The metabolic fate of thalidomide. Experentia 1962; 18: 389
- Gunzler V, Hanauske-Abel H M, Tschank G, Schulte-Wissermann H. Immunological effects of thalidomide: Inactivity of the drug and several of its hydrolysis products in mononucleocyte proliferation tests. Amerein-Forsch/Drug Res. 1986; 36(11)1138–41
- Lonnemann G, Endres S, Van der Meer J WM, Cannon J G, Koch K M, Dinarello C A. Differences in the synthesis and kinetics of release of interleukin 1α, interleukin 1β and tumor necrosis factor from human mononuclear cells. Eur. Immunol 1989; 19: 1531–36
- Barns P F, Chatterjee D, Brennan P J, Rea T H, Modlin R L. Tumor nercosis factor production in patients with leprosy. Inf Immun. 1992; 60(4)1441–46
- Shannon E J, Ejigu M, Haile-Mariam H S, Berhan T Y, Tasesse G. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4± cells in peripheral blood. Lep. Rev 1992; 63: 5–11
- Bhattacharya S N, Chattopadhaya D, Saha K. Tumor necrosis factor: status in reactions in leprosy before and after treatment. Int J of Dermatology 1993; 32(6)436–39
- Gomez M, Partida S, Favila L, et al. Tumor necrosis factor (TNF) in leprosy patients with type II reaction. Abstracts of the 14th International Leprosy Congress, p. 101A, Orlando, Aug 29-Sept 4, 1993, 11
- Sarno E N, Grau G E, Vieira L MM, Nery J A. Serum levels of tumor necrosis factor-α and interleukin-1β during leprosy reactional states. Clin Ex. Immunol 1991; 84: 103–8
- Tracey K J, Cerami A. Cachectin/tumor necrosis factor and other cytokines in infectious disease. Curr Opi. Immunol 1989; 1: 454–61
- Jacob C O. Tumor necrosis factor α in autoimmunity: pretty girl or old witch?. Immunol Today 1992; 13(4)121–25
- Leibovich S J, Polverini P J, Shepard H M, et al. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature 1987; 329: 630–32
- Fràter-Schröder M, Risau W, Hallmann R, Gautschi P, Böhlen P. Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Aca Sci 1987; 84: 5277–81
- Fajardo L F, Kwan H H, Kowalski J, Prionas S D, Allison A C. Dual role of tumor necrosis factor-α in angiogensis. Amer J Path 1992; 140(3)539–44
- Piguet P F, Grau G E, Vassalli P. Subcutaneous perfusion on tumor necrosis factor local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Amer J Path 1990; 136(1)103–10
- Vlassara H, Brownlee M, Manogue K R, Dinarello C A, Pasagian A. Cachectin/TNF and IL-1 by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 249: 1546–48
- Shalaby M R, Palladino M A, Hirabayashi S E, Eessalu T E, Lewis G D, Shepard H M, Aggarwal B B. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J of Leu. Biol 1987; 41: 196–204
- Otsuka Y, Nagano K, Nagano K, Hori K, Ichi J, Ishi O, Hayashi H, Watanabe N, Niitsu Y. Inhibition of neutrophil migration by tumor necrosis factor: ex vivo, in vivo studies in comparison with in vitro effects. Immunol 1990; 145: 2639–43
- Shibata Y., Sasaki K., Nishimura K., Hasimoto Y., Iwasaki S. Enhacement of phorbol ester-induced production of tumor nercosis factor-α by 2, 6-dimethyphenyphthalimide. Biol. Phar. Bull. 1994; 17(11)1532–1534